Conv. Plasma
Nigella Sativa

All curcumin studies
Meta analysis
study COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Ventilation 86% ICU admission 67% Hospitalization time 10% Hospitalization time (b) 17% Recovery time, fever 32% Recovery time, dyspnea 36% Recovery time, fever (b) 4% Recovery time, dyspnea (b) -5% Ct increase 44% Curcumin  Sankhe et al.  LATE TREATMENT  RCT Is late treatment with curcumin + combined treatments beneficial for COVID-19? RCT 120 patients in India (June - November 2020) Faster recovery (p=0.001) and improved viral clearance (p=0.0026) Sankhe et al., Complementary Therapies.., Mar 2022 Favors curcumin Favors control

A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

Sankhe et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824
Mar 2022  
  Source   PDF   All   Meta
Curcumin for COVID-19
14th treatment shown to reduce risk in February 2021
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurcov contains curcuma longa, go ark, sphatika (alum), sita (rock candy), godugdham (bos indicus) milk, and goghritam (bos indicus ghee).
This is the 11th of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 16th of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of death, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 60 (1.7%), control 3 of 60 (5.0%), NNT 30.
hospitalization time, 10.0% lower, relative time 0.90, p = 0.40, treatment 45, control 45, moderate group.
hospitalization time, 16.7% lower, relative time 0.83, p = 0.20, treatment 15, control 15, severe group.
recovery time, 31.9% lower, relative time 0.68, p < 0.001, treatment 45, control 45, moderate group, fever.
recovery time, 36.1% lower, relative time 0.64, p < 0.001, treatment 45, control 45, moderate group, dyspnea.
recovery time, 4.3% lower, relative time 0.96, p = 0.74, treatment 15, control 15, severe group, fever.
recovery time, 4.8% higher, relative time 1.05, p = 0.10, treatment 15, control 15, severe group, dyspnea.
relative Ct increase, 44.4% better, RR 0.56, p = 0.003, treatment mean 9.98 (±6.39) n=44, control mean 5.55 (±6.91) n=43, moderate group.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sankhe et al., 25 Mar 2022, Single Blind Randomized Controlled Trial, India, peer-reviewed, 10 authors, study period June 2020 - November 2020, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary. Contact: (corresponding author),,,,,,,,,
This PaperCurcuminAll
A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
Dr Ajay Prabhakar Sankhe, Nanasaheb Somnath Memane, Vijaykumar P Gawali, Sonal Nanasaheb Memane, Ganesh Ramakrishnan, Tapanendu Kundu, Mayur Nimba Bagul, Ashotosh Kumar, Vikram Bansal, Rashmi Tiwari
Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824
Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India., Complementary Therapies in Medicine, (2021)
As we did not observe any increased risk of adverse events, albeit superior benefits, Ayurcov as an adjuvant to standard of care can be considered in clinical practice. Contributors: Conception and design: Dr. Ajay Conflict of interest: Authors do not have any conflict of interest. Page 21 of 33 Study is funded by Sarveshwar Seva Sahkar Sanstha. However, it has no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Footnotes: 1. Eligibility criteria were evaluated on Day-1 after informed consent procedure. For the study purpose first day is defined as randomization visit day, on which rRTPCR test was carried out. 2. Vital signs included blood pressure, pulse rate, and oxygen saturation. 3. Demographic characteristics captured included age, gender, and date of admission. Other clinical features capture include fever, cough, cold, breathlessness, body ache, diarrhoea, tastelessness, loss of smell, concomitant diseases (diabetes, hypertension, ischaemic heart disease, and renal disease), rRT-PCR values, and outcomes (discharge/death). 4. Ayurcov medication was a single day regimen, with 10 ml dose constituted medicine, three times a day. 5. Specimen samples included swabs from the nose/throat/both nose and throat/nasopharyngeal sites. Specimens collected were kept in 2-8°C ice bags and immediately transported to the laboratory. Nucleic acid..
Agnivesha, Charak Samhita with Ayurveda Deepika commentary by Chakrapani Datta
Ajinkya, Yogesh, Varsha, Reshma, Avinash, Physicochemical Study of Gomutra and formulation of Gomutra ARK, Journal of Pharmacy and Biological Sciences
Bonfoh, Zinsstag, Farah, Simbé, Alfaroukh et al., Raw milk composition of Malian Zebu cows (Bos indicus) raised under traditional system, Journal of Food Composition and Analysis
Devi, Srivastava, Dwivedi, A critical review of concept of aging in Ayurveda, Ayu
Dilip Pandkar, Sachdeva, Pathophysiology of Covid-19 and host centric approaches in Ayurveda, Journal of Ayurveda and Integrative Medicine
Garde, Vagbhat Sanhita
Hotez, Strych, Bottazzi, COVID-19 vaccines: neutralizing antibodies and the alum advantage, Nature Reviews Immunology
J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f
Jaiswal, Williams, A glimpse of Ayurveda -The forgotten history and principles of Indian traditional medicine, J Tradit Complement Med
Kaushik, Jain, Rai, Therapeutic Potentials of Cow Derived Products-A Review, Int J Pharm Sci Res
Kumar, Naik, Ghee: Its properties, importance and health benefits, Lipid Universe
Liu, Yang, Zhang, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci
Mckee, Munks, Macleod, Fleenor, Van Rooijen et al., Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity, The Journal of Immunology
Minochecherhomji, Bio-enhancing properties of cow urine -a review, Int. J. Innov. Res. Sci., Eng., Techn
Mukherjee, Harwansh, Bahadur, Banerjee, Kar et al., Development of Ayurveda -Tradition to trend, J Ethnopharmacol
Osuchowski, Winkler, Skirecki, Cajander, Shankar-Hari et al., The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity, Lancet Respir Med
Randhawa, Cow urine distillate as bioenhancer, J Ayurveda Integr Med Oct
Randhawa, Sharma, Chemotherapeutic potential of cow urine: A review, Journal of intercultural ethnopharmacology
Rastogi, Ayurveda co-interventions have supported complete recovery in severe COVID-19 infection with a chest severity score 18/25: A case report, J Ayurveda Integr Med
Rastogi, COVID-19-affected family treated at home through integrative approach: Upbringing the concept of ayurvedic family physician for COVID cluster management, Journal of Ayurveda Case Reports
Rastogi, Pandey, Singh, COVID-19 pandemic: A pragmatic plan for ayurveda intervention, J Ayurveda Integr Med, doi:10.1016/j.jaim.2020.04.002
Ruscitti, Berardicurti, Benedetto, Cipriani, Iagnocco et al., Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm, Front Immunol
Samhita, Chaukhamba Bharti Academy
Samhita, Sutra Sthana,1/70
Sanhita, Dr Brahmanand Tripathi, Prakashan, Nidansthan
Sanhita, Purvardha, Chaukhamba Samskrut Sanstahan
Sanhita, Sutrasthan
Sankhe, Memane, Gawali, Memane, Bagul et al., Retrospective evaluation of the efficacy, safety and satisfaction of AyurCoro3: A patientreported outcomes study, Journal of Ayurveda and Integrated Medical Sciences
Sankhe, Memane, Gawali, Memane, Bagul et al., Use of "AyurCoro-3" as a prophylactic drug in frontline healthcare workers involved in treating COVID-19 patients: A pilot study, International Journal
Sankhe, Memane, Gawali, Memane, Ramakrishnan et al., A prospective, multi center, single blind, randomized controlled study evaluating "AyurCoro3" as an adjuvant in the treatment of mild to moderate COVID-19 patients, Journal of Ayurveda and Integrated Medical Sciences
Schulz, Altman, Moher, Group, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ
Tang, Schmitz, Persing, Stratton, Laboratory diagnosis of COVID-19: current issues and challenges, Journal of clinical microbiology
Tillu, Chaturvedi, Chopra, Patwardhan, Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis, J Altern Complement Med, doi:10.1089/acm.2020.0129
Yang, Islam, Wang, Li, Chen, Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective, International journal of biological sciences
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zeenat, An appraisal of medicinal properties of Shibb-e-Yamani (Alum): A review, UniMed-Kulliyat
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop